ROSELAND, N.J., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) today announced that President and Chief Executive Officer, Alan L. Rubino, will present at the SeeThruEquity MicroCap Investor Forum at 9:30 AM ET on Thursday, November 12, 2015. The SeeThruEquity conference is being held at the Convene Grand Central in New York City.
Emisphere’s presentation will be webcast live the day of the SeeThruEquity conference, and will be available on the company’s website at ir.emisphere.com/events.cfm. An archive of the webcast will be available for 90 days following the day of the conference and can be accessed by following the same link.
Emisphere is a commercial-stage pharmaceutical and drug delivery company that has recently commenced commercial operations. The Company launched its first prescription product, oral Eligen B12™, in the U.S. in March 2015 and is in partnership with global pharmaceutical companies to develop new formulations of existing products, as well as new chemical entities, using its Eligen® Technology. Beyond Eligen B12, the Company utilizes its proprietary Eligen® Technology to create new oral formulations of therapeutic agents. Emisphere’s product pipeline includes prescription drug and medical food product candidates that are being developed in partnership or internally. For more information, please visit www.emisphere.com.
COMPANY CONTACTS: Alan L. Rubino, CEO 973.532.8000 firstname.lastname@example.org Michael R. Garone, CFO 973.532.8005 email@example.com INVESTOR CONTACTS: Susan Kim Argot Partners (212) 600-1902 firstname.lastname@example.org
Source:Emisphere Technologies, Inc.